Press Releases

BEIJING, June 16, 2024 /PRNewswire/ -- For Chinese President Xi Jinping, words and deeds of his father Xi Zhongxun (1913-2002) embodying the principle of "being a public servant of the people" are a great family heirloom that runs deep in his outlook on life, work, and philosophy.

In the exhibition hall of the premises of the former prefectural Party committee of Suide of northwest China's Shaanxi Province , one line of words is... (continue reading...)

First and only BTK inhibitor to demonstrate favorable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive results from the ECHO Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and showed a favorable trend in overall... (continue reading...)

At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously published in the Journal of Clinical Oncology

Also presented at EHA, a retrospective study of patient outcomes that compared investigational linvoseltamab to real-world standard-of-care treatment in clinical practice

TARRYTOWN, N.Y., June 16, 2024 (GLOBE NEWSWIRE) --... (continue reading...)

PARIS--(BUSINESS WIRE)-- Please replace the release dated June 12, 2024 with the following corrected version due to multiple revisions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240607090059/en/

Liby Master Fragrance made its debut in Grasse (Photo: Business Wire)

The updated release reads:

LIBY MASTER FRAGRANCE FROM CHINA UNLOCKS PREMIUM FRAGRANCE MARKET IN GRASSE

In May 2024, the Liby Master... (continue reading...)

Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations

Clinical responses in CLL patients were rapid and deepening with longer time on treatment

Nurix intends to advance NX-5948 into pivotal trial(s) in 2025

Company will host a webcast conference today, June 16, 2024, at 9:00 a.m. ET (3:00 p.m. CEST)

SAN FRANCISCO, June 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics,... (continue reading...)